The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Dr Reid Merryman | ASH 2017 | What is the role of different immunotherapies in DLBCL?

Jan 3, 2018

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Dr Reid Merryman
Dana-Farber/Harvard Cancer Center, Boston, US

Interview topic: What is the role of different immunotherapies in DLBCL (Checkpoint inhibitors and engineered T-cell therapy)?

Dr Reid Merryman | ASH 2017 | What is the role of different immunotherapies in DLBCL?